Commercial bacterins did not induce detectable levels of antibodies in mice against Mycoplasma hyopneumoniae antigens strongly recognized by swine immune system

Fisch, Andressa; Marchioro, Silvana Beutinger; Gomes, Charles; Galli, Vanessa; Oliveira, Natasha Rodrigues de; Simionatto, Simone; Dellagostin, Odir A.; Mendonça, Marcelo; Moreira, Ângela Nunes; Conceição, Fabrício Rochedo

doi:10.1016/j.trivac.2016.01.001

Cited by 9 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Analyses of lymphocyte proliferation levels and total IgG and IgG isotype levels show that lymphocytes or sera from the Mhp CV group did not react with all the antigens. This can be ascribes to the commercial Mhp vaccine strain does not produce these antigens or expressed them at low levels, which was similar to the results of other researchers [4,5,15,23,40]. For the detection of Mhp strain 168 and PCV2 strain ZJ/C extracts as antigens, serum showed good reactivity with native proteins from these two strains (Fig.…”

Section: Discussionsupporting

confidence: 89%

“…Currently, the main vaccines for MPS and PCVD/ PCVAD are inactivated vaccines and attenuated vaccines. However, some studies have shown that these commercial vaccines for MPS could not induce satisfied levels of antibodies against Mhp antigens [23]. Therefore, there may still be some defects in commercial vaccines, although these commercial vaccines were prevalent used in swine industry.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immune responses induced by a combined vaccination with a recombinant chimera of Mycoplasma hyopneumoniae antigens and capsid virus-like particles of porcine circovirus type 2

Yang

Shu

et al. 2020

BMC Vet Res

View full text Add to dashboard Cite

Background Mycoplasma hyopneumoniae (Mhp) and porcine circovirus type 2 (PCV2) are two important pathogens causing Mycoplasma pneumonia of swine (MPS) and porcine circovirus diseases and porcine circovirus-associated diseases (PCVDs/PCVADs), respectively, and resulted in considerable economic loss to the swine industry worldwide. Currently, vaccination is one of the main measures to control these two diseases; however, there are few combination vaccines that can prevent these two diseases. To determine the effect of combination immunization, we developed capsid-derived (Cap) virus-like particles (VLPs) of PCV2 and a new recombinant chimera composed of the P97R1, P46, and P42 antigens of Mhp. Then we investigated the immune responses induced by the immunization with this combination vaccine in mice and piglets. Results The high level antibodies against three protein antigens (P97R1, P46, and P42 of Mhp) were produced after immunization, up to or higher than 1:400,000; the antibody levels in Pro group continuously increased throughout the 42 days for all the antigens tested. The lymphocyte proliferative response in PCV2 group was stronger than that in PBS, VP, Mhp CV in mice. The antibody levels for Cap remained stable and reached the peak at 35 DAI. The IFN-γ and IL-4 in sera were significantly enhanced in the Pro group than that in the negative control-VP group on Day 14 and 28 post-the first immunization in piglets. Conclusions Above all, the combination immunization could induce humoral and cellular immune responses against all four antigens in mice and piglets. Therefore, our approach is a simple and effective vaccination strategy to protect pigs against MPS and PCVD/PCVAD.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Immune responses induced by a combined vaccination with a recombinant chimera of Mycoplasma hyopneumoniae antigens and capsid virus-like particles of porcine circovirus type 2

Yang

Shu

et al. 2020

BMC Vet Res

View full text Add to dashboard Cite

show abstract

“…Estos resultados son compatibles con los hallazgos de Sun (2009), quién reportó una pobre inmunogenicidad estimulada por una bacterina de P. multocida inoculada en ovejas. Esta ineficacia de las bacterinas también se ha observado en estudios con Mycoplasma hyopneumoniae (Fisch et al, 2016), Actinobacillus pleuropneu-moniae (Shao et al, 2010) y Streptococcus suis (Hsueh et al, 2017). Este suceso podría deberse a la composición múltiple de la bacterina que conlleva a una pobre estimulación de los centros germinativos (Siegrist, 2008).…”

Section: Discussionunclassified

“…Este suceso podría deberse a la composición múltiple de la bacterina que conlleva a una pobre estimulación de los centros germinativos (Siegrist, 2008). Esto también ha podido ocurrir debido a la disminución en la concentración de las proteínas P6-like expresadas por la cepa de P. multocida por la «domesticación» de la cepa laboratorial (Fisch et al, 2016).…”

Section: Discussionunclassified

Evaluación de la inmunogenicidad de una proteína recombinante de Pasteurella multocida para la prevención de la neumonía aguda en alpacas (Vicugna pacos)

Moreno-Morales

Maximiliano

Siuce

et al. 2021

Rev. investig. vet. Perú

View full text Add to dashboard Cite

El objetivo del presente estudio fue evaluar la capacidad inmunogénica in vivo de una proteína recombinante de membrana externa de Pasteurella multocida denominada P6-like (rP6-like). El ensayo de campo se realizó en una unidad de producción alpaquera en Puno, Perú, y el procesamiento de las muestras en la Facultad de Medicina Veterinaria de la UNMSM. Se formaron 4 grupos de 5 animales, y se inoculó, según el grupo a) solución salina normal, b) bacterina, c) rP6-like, d) combinación de bacterina + rP6-like. Se tomaron muestras de sangre en el día 0, 5, 7, 9, 12 y 15 pos-inoculación. Se diseñaron pruebas de ELISA indirecto de punto único para la cuantificación relativa de anticuerpos específicos anti rP6-like y para anticuerpos anti-proteína total de P. multocida. El grupo inoculado con rP6-like mostró elevación significativa de anticuerpos desde el día 7 (p<0.05) hasta el día 15 pos-inoculación. Los demás productos biológicos no presentaron elevación significativa durante el periodo del estudio. El estudio permitió evidenciar la capacidad inmunogénica de la rP6-like, lo cual permite continuar con futuros estudios de eficacia.

show abstract

“…Similar results also appeared in other studies. Many other researchers found that Mhp commercial vaccines are not effective in mouse immunization experiments [9,10,26,27,28]. However, similar commercial vaccines have been proved to be safe and effective in experimental or field conditions of piglet immunization [7,29,30,31].…”

Section: Discussionmentioning

confidence: 99%

Development of a Combined Genetic Engineering Vaccine for Porcine Circovirus Type 2 and Mycoplasma Hyopneumoniae by a Baculovirus Expression System

Zheng

et al. 2019

IJMS

View full text Add to dashboard Cite

Mycoplasma hyopneumoniae (Mhp) and porcine circovirus type 2 (PCV2) are the main pathogens for mycoplasmal pneumonia of swine (MPS) and post-weaning multisystemic wasting syndrome (PMWS), respectively. Infection by these pathogens often happens together and causes great economic losses. In this study, a kind of recombinant baculovirus that can display P97R1P46P42 chimeric protein of Mhp and the capsid (Cap) protein of PCV2 was developed, and the protein location was identified. Another recombinant baculovirus was constructed without tag proteins (EGFP, mCherry) and was used to evaluate the immune effect in experiments with BALB/c mice and domestic piglets. Antigen proteins P97R1P46P42 and Cap were expressed successfully; both were anchored on the plasma membrane of cells and the viral envelope. It should be emphasized that in piglet immunization, the recombinant baculovirus vaccine achieved similar immunological effects as the mixed commercial vaccine. Both the piglet and mouse experiments showed that the recombinant baculovirus was able to induce humoral and cellular responses effectively. The results of this study indicate that this recombinant baculovirus is a potential candidate for the further development of more effective combined genetic engineering vaccines against MPS and PMWS. This experiment also provides ideas for vaccine development for other concomitant diseases using the baculovirus expression system.

show abstract

Commercial bacterins did not induce detectable levels of antibodies in mice against Mycoplasma hyopneumoniae antigens strongly recognized by swine immune system

Cited by 9 publications

References 42 publications

Immune responses induced by a combined vaccination with a recombinant chimera of Mycoplasma hyopneumoniae antigens and capsid virus-like particles of porcine circovirus type 2

Immune responses induced by a combined vaccination with a recombinant chimera of Mycoplasma hyopneumoniae antigens and capsid virus-like particles of porcine circovirus type 2

Evaluación de la inmunogenicidad de una proteína recombinante de Pasteurella multocida para la prevención de la neumonía aguda en alpacas (Vicugna pacos)

Development of a Combined Genetic Engineering Vaccine for Porcine Circovirus Type 2 and Mycoplasma Hyopneumoniae by a Baculovirus Expression System

Contact Info

Product

Resources

About